Ken Griffin Esperion Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$1.61 - $2.73 $50,876 - $86,268	31,600 Added 76.89%	72,700 $119,000
Q2 2024 Aug 14, 2024	SELL	$1.84 - $3.24 $195,776 - $344,736	-106,400 Reduced 72.14%	41,100 $91,000
Q1 2024 May 15, 2024	BUY	$2.02 - $3.02 $172,306 - $257,606	85,300 Added 137.14%	147,500 $395,000
Q4 2023 Feb 14, 2024	BUY	$0.73 - $3.08 $6,059 - $25,564	8,300 Added 15.4%	62,200 $185,000
Q3 2023 Nov 14, 2023	SELL	$0.96 - $1.79 $100,320 - $187,055	-104,500 Reduced 65.97%	53,900 $52,000
Q2 2023 Aug 14, 2023	SELL	$1.2 - $1.76 $32,640 - $47,872	-27,200 Reduced 14.66%	158,400 $220,000
Q1 2023 May 15, 2023	SELL	$1.46 - $7.3 $330,690 - $1.65 Million	-226,500 Reduced 54.96%	185,600 $295,000
Q4 2022 Feb 14, 2023	BUY	$5.09 - $8.5 $1.03 Million - $1.72 Million	202,500 Added 96.61%	412,100 $2.57 Million
Q3 2022 Nov 14, 2022	BUY	$5.45 - $8.13 $282,855 - $421,947	51,900 Added 32.91%	209,600 $1.4 Million

208

128M

1.67M

930K

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $160M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.